Rapid Therapeutic Science Laboratories, Inc.
RTSL
Other OTC0.00
USD
- -
- -
Rapid Therapeutic Science Laboratories, Inc.
RTSL
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Rapid Therapeutic Science Laboratories, Inc. operates as a biopharmaceutical company specializing in developing and manufacturing aerosol delivery systems for cannabinoid-based therapeutics. The company’s primary products include pressurized metered dose inhalers (pMDIs) under the nhāler brand that deliver pharmaceutical-grade proprietary blends of non-psychoactive cannabinoid compounds such as cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). These inhalers offer rapid absorption through pulmonary administration, targeting medical and alternative medicine markets. In addition to MDIs, the company manufactures other aerosol devices for cannabinoid delivery, including sublingual sprays. All products are manufactured in compliance with Good Manufacturing Practices (GMP) on FDA-listed equipment. Rapid Therapeutic Science Laboratories focuses on providing safe, heat-free, and highly bioavailable cannabinoid aerosol therapies as alternatives to conventional vaping devices. Founded in 2020 and headquartered in Dallas, Texas, Rapid Therapeutic advances arena innovation through proprietary pharmaceutical-grade cannabinoid formulations and aerosol manufacturing technologies. The company recently completed a $14 million acquisition of Razor Jacket, enhancing its vertical integration by enabling in-house manufacturing of pharmaceutical-grade cannabinoid isolates. This acquisition supports the production of combined cannabinoid and terpene formulations, reinforcing its capacity to innovate and control quality. Additionally, Rapid Therapeutic has transitioned three proprietary pharmaceutical grade patents from provisional to non-provisional status, related to inhalation formulations of CBD and CBG, and intends to pursue further patents for THC-based inhalants. Recently, Rapid Therapeutic has strategically pivoted towards regulatory approval and pharmaceutical R&D, aiming to file an Investigational New Drug (IND) application with the U.S. FDA for its novel CBD metered dose inhaler. The company plans Phase 1 human clinical trials for this flagship product and continues to develop complementary cannabinoid aerosol therapeutic offerings. It expanded operations by opening an 8,566 square foot manufacturing facility in Addison, Texas, which complies with ISO 13485 standards and GMP practices, increasing production capacity and operational efficiency with significantly reduced costs. The governance structure has been strengthened by the appointment of independent directors with medical and management expertise, aligning with aspirations to uplist on a major stock exchange. Rapid Therapeutic operates primarily in the healthcare/cannabis pharmaceutical sector with a market focus on non-psychoactive cannabinoid therapeutics delivered via innovative aerosol technology in the United States. Its business model centers on combining natural cannabinoid relief with scientifically advanced and regulated inhaler delivery systems, targeting both consumer wellness and clinical therapeutic segments. The company maintains SEC fully-reporting status and markets its products primarily under the nhāler and Rxoid brands, emphasizing compliance, safety, and high bioavailability of cannabinoid compounds. In summary, Rapid Therapeutic Science Laboratories, Inc. develops, manufactures, and commercializes pharmaceutical-grade cannabinoid aerosol delivery products, recently enhanced by a key acquisition to support in-house isolate production, patent progressions, regulatory filings for FDA approval, and facility expansion to increase manufacturing capabilities and operational efficiency. The company continues its strategic focus on growing cannabinoid aerosol therapeutics through clinical validation and regulatory approval pathways in the U.S. market.
Rapid Therapeutic Science Laboratories to Present at the Q4 Investor Summit Conference